NasdaqGS:IDYABiotechs
IDEAYA Biosciences (IDYA) Stock Could Be 81.5% Below Fair Value After Trial Milestone
IDEAYA Biosciences (IDYA) stock is in focus after the company enrolled the first patient in a Phase 1 trial that combines IDE892 and IDE397 for MTAP-deleted solid tumors, including pancreatic and non-small cell lung cancers.
See our latest analysis for IDEAYA Biosciences.
At a share price of $30.57, IDEAYA Biosciences has seen strong short term momentum, with a 7 day share price return of 10.76% and a 30 day share price return of 7.94%. However, the 90 day share price return declined 6.23%,...